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ABSTRACT
In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir 
(BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis 
C, after their approval by the National Committee for Health Technology Incorporation 
(CONITEC). However, these medicines were discontinued in 2015. The short period of 
use in therapy and their high cost require a discussion about the consequences for patients 
and for the health system of the early incorporation of new therapies. The article presents a 
qualitative analysis of the incorporation process of both medications in Brazil and the results 
of a multicenter study that included patients treated with BOC or TVR between January 
2011 and December 2015 in five Brazilian cities. The study included 855 patients (BOC: 
n=247) and (TVR: n=608). The document analysis showed that CONITEC’s decision to 
incorporate BOC and TVR was based on results of phase III clinical trials that compared 
sustained virologic response (SVR) rates of patients treated with BOC and TVR with 
rates of those that received placebo. However, these studies included a low percentage 
of cirrhotic patients. The SVR rates observed in this multicenter study were worse than 
clinical trials pointed out (BOC: 45.6%; TVR: 51.8%), but similar to those achieved with 
previously adopted therapies. The discontinuation rate due to adverse events was (BOC: 
15.4%; TVR: 12.7%). Based on these unsatisfactory results, the study brings a discussion 
that goes beyond the therapy outcomes, exploring the incorporation of these high-cost 
medicines and the related decision-making process, contributing to future decisions in 
medicine policies and in the treatment of chronic hepatitis C. 
KEYWORDS: Chronic hepatitis C treatment. Protease inhibitors. High cost medicines. 
Real life studies.
INTRODUCTION
Decisions in clinical and health policies require careful weighing of risks and 
benefits. It involves the health and quality of life of treated patients and mobilizes 
a large amount of public funds. Scientific evidence must guide this process along 
with the analysis of health gain returns in different social scenarios. This fact comes 
into sharp focus in the case of the introduction of new therapies to treat chronic 
hepatitis C (CHC) in Brazil.
Treatment of hepatitis C virus (HCV) infection rapidly evolved in the last 
two decades. The first-generation protease inhibitors (PIs) boceprevir (BOC) and 
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telaprevir (TVR) have emerged as a breakthrough in terms 
of effectiveness and safety. As of 2011, these drugs were 
approved by regulatory agencies, also in Brazil and marked 
a unique event, with two new drugs launched simultaneously 
for the same disease1,2. However, these treatments were 
much more expensive than previous therapies, leading the 
health systems, both public and private, to have limit access 
to patients in advanced stages of the disease3,4.
In Brazil, the public health system (Unified Health 
System – SUS) is responsible for providing the HCV 
therapy. In 2012, the National Committee for Health 
Technology Incorporation (CONITEC) recommended 
the introduction in SUS of TVR and BOC for use with 
pegylated interferon (PEG-INF) and ribavirin (RBV), 
the “triple therapy”, for patients with genotype 1 HCV in 
advanced clinical conditions5,6.
The process-making decision to incorporate these 
pharmaceutical technologies in SUS started by public 
requirements to the CONITEC. A set of requirements 
were submitted by public applicants, including: number 
and validity of the technology registration in the National 
Health Surveillance Agency (ANVISA); scientific 
evidence showing that the technology is at least as effective 
and safe as those available in SUS for the intended use; 
an economic evaluation study comparing the requested 
technology with those available in the SUS. Then, the 
CONITEC’s initial recommendations were submitted for 
public consultation for 20 days. Then, public contributions 
were evaluated and CONITEC deliberated its final 
recommendation to the BOC and TVR incorporation. 
However, the drugs were early discontinued in Brazil in 
mid-2015 due to its adverse events (AEs), costs and low 
effectiveness7. Furthermore, new direct acting drugs, 
such as the second-generation of PIs, simeprevir (SMV)/
(NS3/4A protease inhibitor); daclatasvir (DCV)/(NS5A 
protease inhibitor) and the NS5B viral polymerase 
inhibitor sofosbuvir (SOF), were included in the Brazilian 
guideline8. International phase III and real-life trials have 
indicated that this new generation of DAAs would be more 
effective and safer than TVR and BOC9-11.
Although TVR and BOC are no longer in use for 
treatment of hepatitis C in the SUS, they are still valid in 
ANVISA. Thus, data on the Brazilian experience with the 
triple therapy may be useful in future protocols using these 
drugs, as well as in the analysis of demands for incorporation 
of drugs for treatment of hepatitis C. We analyzed the 
decision-making process on drug incorporation, criteria for 
inclusion of patients in treatment guidelines, expenditure 
on medication purchase and results of the treatment of 855 
patients with chronic hepatitis C compared to the findings 
of clinical trials.
MATERIALS AND METHODS
Analysis of the decision‑making process of 
incorporation
The decision-making process of BOC and TVR 
incorporation was evaluated based on a qualitative document 
analysis. The three main documents generated during the 
decision-making process were analyzed: CONITEC’s 
minutes of final meeting (official document provided by 
the Ministry of Health); public consultation contributions12 
and CONITEC’s final deliberation6.
Criteria for inclusion of patients in the clinical trials cited 
in the guidelines were compared with socio-demographic 
and clinical data of the real life treatment.
Expenditure on the purchase of TVR and BOC was 
provided through e-Sic (Electronic System of the Citizen 
Information Service), adjusted by the National Consumer 
Price Index / year (2012: 1.37; 2013: 1.27; 2014: 1.20; 2015: 
1.16) and calculated in UDS (Dollar exchange rate 3.18). 
Real life treatment
This retrospective study enrolled 855 patients with 
HCV-genotype 1 chronic infection from different regions of 
Brazil: South (cities of Florianopolis-SC, Porto Alegre-RS 
and Pelotas-RS), Southeast (city of Ribeirao Preto-SP) and 
Northeast (city of Salvador-BA). All patients were treated 
with PEG-INF-2a or 2b, RBV and either TVR or BOC 
provided by the Brazilian health system from January 2011 
to December 2015. 
Data were collected from the patients’ records by 
means of a standardized form including demographics, 
medical history and information on treatment outcomes. 
Data on treatment outcomes encompassed SVR, Non-
response, relapse (collected from patients’ laboratory 
exams), discontinuation due to adverse events (AEs), 
treatment withdrawal and death. SVR was defined as the 
maintenance of negative HCV RNA 24 weeks after the 
end of the treatment and was calculated by intention-to-
treat analysis. The AEs implicated in case of treatment 
discontinuation were grouped as per hematologic events 
(anemia, neutropenia, thrombocytopenia, bleeding and 
thrombosis), cutaneous reactions (rush, pruritus and dry 
skin) or other (renal dysfunction, liver decompensation, 
sepsis, peripheral neuropathy and psychiatric disorders). 
All patients included in the study were treated in 
accordance with the Brazilian guidelines5. The Clinical 
Protocol and Therapeutic Guidelines (PCDT) for hepatitis 
C treatment indicates a combination of TVR (750 mg, 3 
times a day) or BOC (800 mg, 3 times a day) associated 
Rev Inst Med Trop São Paulo. 2018;60:e29
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
Page 3 of 8
with PEG-IFN-2a (180 mcg) or 2b (1.5 mcg/kg) once a 
week plus RBV (weight-adjusted dose, daily). The use of 
TVR could be initiated on the first week of treatment or 
after 4 weeks using PR (lead-in phase) and was continued 
for 12 weeks, then it went on with only PR for 36 weeks. 
For the BOC regimen, lead-in phase was required and 
triple therapy was conducted for 44 weeks. During both 
therapeutic regimens, the Polymerase Chain Reaction 
(PCR) was performed to guide suspension or continuation 
of treatment. To TVR or BOC schemes, the therapy was 
discontinued whether viral load (VR) > 1,000 UI/mL on 
the 4th or 12th or 24th weeks. Discontinuation was performed 
if VR > 100 UI/mL on the 12th week or VR detectable on 
the 24th week of the therapy5.
Ethics Statements
The study was approved by the Ethics Committee on 
Human Research of the authors’ institutions (Protocol 
Nº 27185514.3.1001.0121). 
Statistical Methods
A unified database comprising data collected in all 
research centers was created using the Excel software. The 
statistical analysis was performed using the software STATA 
version 14 - License 301406276417 - (Stata Corp, College 
Station, USA). Demographics and clinical characteristics 
were compared as per treatment (BOC or TVR) using the 
Chisquare tests or the Fisher exact test. 
RESULTS
Results of document analysis
Analysis of the CONITEC’s minutes of final meeting 
showed that the decision for the incorporation of BOC 
and TVR was based on the results of efficacy studies 
(phase III clinical trials) of both medicines, presented by 
a pharmaceutical industry consultant. According to the 
document description, the presented studies compared SVR 
rates of patients in advanced fibrosis levels (F3 and F4) 
with those of patients who received placebo. The consultant 
emphasized that the BOC’s study did not evaluate the 
treatment response for cirrhotic patients, due to the low 
percentage of these patients in the study. The main adverse 
events associated with the use of BOC and TVR were also 
presented and consisted of anemia, altered taste, dry skin, 
rash and anorectal symptoms. Finally, at the end of the 
meeting, CONITEC members asked some questions to the 
consultant and decided, by a simple majority, to incorporate 
BOC and TVR for treatment of CHC, and requested the 
public consultation.
Concerning the analysis of the public consultation 
results, educational institutions, associations related to 
patients and the pharmaceutical company gave contributions. 
No evidence was found regarding public manifestations 
contrary to the medicines incorporation. According to the 
public consultation document, most contributions requested 
details of the of BOC and TVR indication, for example, 
criteria for patients’ inclusion (request for the inclusion of 
patients F2), which was not followed by CONITEC. The 
general analysis of the CONITEC’s final deliberation (after 
public consultation) did not show any relevant findings. 
Expenditure on BOC and TVR purchase
In the period 2013-2015, the Ministry of Health 
spent more than 220 million dollars on the acquisition of 
BOC and TVR. Considering the treatment duration and 
the posology recommended in the Clinical Protocol and 
Therapeutic Guidelines, the quantity purchased would 
allow the treatment of approximately 14,000 to 18,000 
individuals (Table 1). 
Results of BOC and TVR “real world” outcomes
The study included 855 patients of whom 247 (28%) 
used BOC and 608 (72%) TVR. Table 2 shows demographic 
and clinical characteristics as per treatment, all equally 
distributed between both treatments. Most patients were 
male 564 (66%) and white 451 (86.9%). The mean age 
was 54 years (SD = 8.8), ranging from 20 to 78 years. 
Concerning the clinical characteristics, most patients 
presented cirrhosis (BOC: 37.0%; TVR: 41.4%) and F3 
score (BOC: 30.6%; TVR: 36.4%) and received prior HCV 
treatment (BOC: 61.2%; TVR: 54.4%). 
The outcomes are described in Table 3 as per treatment 
regimen. Among the patients treated with BOC or TVR, 
45.6% and 51.8% achieved SVR, respectively.
DISCUSSION
Shortly after FDA approval, the first generation of DAA, 
the protease inhibitors BOC and TVR, were introduced in 
the health system of many countries1-3. The approval of 
new drugs came with expectation of the addition of either 
BOC or TVR to PEG and RBV would higher significantly 
SVR rates. As comparative safety and effectiveness data 
in real-world populations with comorbidities or relative 
contraindications upon which to make formulary decisions 
did not exist, the new guidelines was supported just by 
Gomes et al.
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Table 1 - The amount invested in the purchase of TVR and BOC medicines in Brazil between 2013 and 2015 (in US million dollars) 
Drugs Amount Average cost per unit U$ Custs U$
Estimated number of 
treatments*
Boceprevir 200mg (capsule) 4,955,664 4.46 21,242,289.49 1,341
Telaprevir 375mg (tablete) 6,485,292 31.56 203,151,973.67 12,868 to 17,157
TOTAL 224,394,263.17 14,208 to18,498
*TVR => considering the dosage of 2 tablets / 8 hour = 6 tablets / day x 12 weeks (84 days) = 504 tablets (beginning in the first 
week) or performed lead‑in (starting from the fourth week) = 63 days = 378 tablets. BOC => considering the dosage of 4 capsules 
/ 8 hours = 12 capsules / day X 44 weeks (308 days) = 3696 capsules. ** Values adjusted by the National Consumer Price Index/
year, ((2013: 1.27); (2014: 1.20); (2015: 1.16).  Dollar exchange rate (3.18) 
Table 2 - Baseline characteristics of the 855 patients enrolled in the study to evaluate the outcomes of the triple therapy with 
boceprevir or telaprevir in Brazil, January 2011 to December 2015
 
boceprevir (n=247) telaprevir (n=608)
P valuea
n % n %
Sociodemographic characteristics
Age, mean 54; SD 8,8
Sex 0.420
   Male 168 68.0 396 65.1
   Female 79 32.0 212 34.9
Skin colorb 0.828
   White 140 86.4 311 87.1




   F0/F1c 14 5.9 13 2.2
   F2 62 26.4 116 19.9
   F3 72 30.6 212 36.4
Cirrhosisd 87 37.0 241     41.4
Activityb 0.397
   A0/A1 76 40.2 172 37.4
   A2 90 47.6 213 46.3
   A3 23 12.2 75 16.3
Comorbidities     
   HIV 6 2.4 18 3.0 0.670
   Diabetes Mellitus 37 15.0 104 17.1 0.462
   Hypertension 66 26.8 201 33.1 0.075
   Obesityb 40 17.8 107 20.0 0.493
   Dyslipidemiab 10 4.4 18 3.2 0.424
   Steatosisb 14 8.6 66 14.1 0.070
Previous Treatmentb 142 61.2 317 54.4 0.076
Treatment Duration <0.0001
   < 24 weeks 58 23.6 171 28.2
   25‑36 56 22.8 63 10.4
   37‑48 132 53.7 373 61.4
Way to access the treatmentb <0.0001
   Adminsitrative 152 61.5 521 85.7
   Lawsuit 88 36.7 82 13.6
aChi square test. bMissing (n): skin color (336); fibrosis, (38); activity,(206 ); obesity ( 93); steatosis (223 ); dyslipidemia (65), Way to 
access the treatment (12) and previous treatment (40). cIn variable F0/F1, patients with METAVIR SCORE F0 and F1 were grouped. 
d For variable cirrhosis, patients with METAVIR SCORE F4 and clinical cirrhosis were grouped
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efficacy and safety demonstrated by clinical trials. As 
presented on the results, the CONITEC’s decision was 
based on comparative efficacy studies with placebo and a 
low percentage of cirrhotic patients. 
The ADVANCE, ILLUMINATE and REALIZE studies 
performed with TVR demonstrated SVR rates of 75%, 
72%, 80% (previous relapse), respectively. The SPRINT-2 
and RESPOND-2 studies performed with BOC showed 
SVR rates of 66%13-16. We found the overall SVR rate for 
treatment with TVR (51.8%) or BOC (45.6%). These results 
are broadly consistent with others from real life studies 
around the world17-23.
We found high discontinued prescription rates due 
to AEs, 15.4% of the patients treated with BOC and 
12.7% with TRV. Hematologic events were the main 
cause of discontinuation of both drugs, followed by 
cutaneous reactions, which were more significant among 
patients treated with TVR (3.1%) than with BOC (1.2%). 
Corroborating our results, a Brazilian cohort study developed 
with 203 patients showed high rates (19.2%) of therapy 
discontinuation owing to AEs. These authors reported that 
41% and 37.5% of the BOC or TVR discontinuations, 
respectively, also occurred due to hematologic events and 
cutaneous reactions20. It was previously described that 
patients with comorbidities and advanced cirrhosis are 
more vulnerable to AEs18,21. Hematologic reactions, as well 
as psychiatric disorders and changes in thyroid function 
are associated with the use of PEG-INF and RBV. Serious 
AEs were the main cause of early discontinuation of triple 
therapy in the Brazilian health system7.
The discrepancy between the outcomes of clinical 
trials and real-life studies may be related to the profile of 
the population of patients enrolled, which was carefully 
selected. Patients treated in trials must meet stringent entry 
criteria, which may do not reflect the population treated in 
routine medical practice. The ADVANCE, ILLUMINATE, 
REALIZE SPRINT-2 and RESPOND-2 clinical trials 
included a low proportion of patients with cirrhosis (3%, 
16%, 18%, 12% and 9%, respectively), or fibrosis without 
cirrhosis and no one with comorbidities in the evaluated 
groups, while our real life study enrolled a higher proportion 
of cirrhosis (BOC: 37.0%; TVR: 41.4%), fibrosis without 
cirrhosis (F3-BOC: 30.6%; TVR: 36.4%) and comorbidities 
as hypertension, obesity, DM, steatosis, dyslipidemia and 
HIV coinfection. It has been reported that cirrhosis is a 
negative predictive factor for successful therapy and patients 
with comorbidities and advanced liver disease are difficult 
to treat and more likely to treatment discontinuation due 
to AEs14,17,18,24-27.
The Brazilian guidelines established that just F2 (for 
more than three years) or F3, F4 or cirrhotic patients were 
entitled for treatment with METAVIR offered by the public 
health system. On the other hand, trials suggested a higher 
efficacy in patients with mild or moderate fibrosis6. The 
improvement of SVR was expected with the triple therapy, 
however, the results was similar to those achieved with 
INF-PEG 2a/2b + RBV regimen-based. Brazilian studies 
that analyzed the dual therapy showed SVR rates between 
40-50%28,29. Additionally, as shown in the results, the public 
investment to acquire the triple therapy was much higher 
when compared with the dual therapy acquisition. 
As mentioned in the introduction, the CONITEC’s 
decision to recommend the triple therapy was also based 
in cost-effectiveness studies supported by clinical trials5. 
Table 3 ‑ boceprevir or telaprevir therapeutic regimen outcomes
 boceprevir (n=247) telaprevir (n=608) P valuea,b
n % n %
SVRc 99 45.6 273 51.8 0.125
No responder 48 19.4 122 20.0 0.104
Abandonment 11 4.5 23 3.8 0.649
Relapsec 37 17.0 61 11.6 0.050
Discontinuation due to AEs 38 15.4 77 12.7 0.291
Hematologic eventsd 18 7.3 38 6.3 0.689
Cutaneous reactionse 3 1.2 19 3.1 0.117
Others eventsf 17 6.9 23 3.8 0.077
Dead 3 1.2 8 1.3 0.905
SVR: sustained virological response. AEs: adverse events. aChi square test. bFisher’s exact test. cMissing (n):  SVR and relapse 
(111), partial responders (25). dHematologic events considered: anemia, neutropenia, thrombocytopenia, bleeding and thrombosis. 
eCutaneous reactions considered: rush, pruritus and dry skin. fOther events considered: renal dysfunction, liver imbalance, sepsis, 
peripheral neuropathy, psychiatric disorders. The total number of outcomes for telaprevir and boceprevir are higher due the same 
patient may present more than one outcome
Gomes et al.
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However, considering the facts pointed out, a question 
comes across: cost-effectiveness studies are substantial 
to support the decision-making process? It is known 
that the aim of the principle of cost effectiveness is to 
ensure that the most health benefits are obtained from the 
available resources. However, it has increasingly been 
recognized that setting health priorities requires not only 
technical judgments such as those around clinical and cost 
effectiveness, but also involves social value judgments30. 
Social value judgments might be defined as judgments 
made on the basis of moral or ethical values of a particular 
society30. In this sense, criteria for patients’ inclusion 
in the Brazilian guidelines are against the constitutional 
universal right to health and means, tearing the principle 
of universality of access to health. In addition, Karen Van 
Nuys et al.31, using a model to simulate the progression of 
a population susceptible to hepatitis C through infection 
and several stages of the disease, demonstrated that treating 
5 percent of the infected population annually regardless of 
the patients’ disease stages, would also return substantial 
social benefits and would be much more affordable, so 
treating patients at earlier stages of liver disease generated 
more value than waiting to treat them when liver damage 
has progressed. 
Outcomes found in this study, when explored on the 
perspective of what does the incorporation of high cost 
medicines by developing countries mean and the decision-
making process related to the necessity of developing 
strategies for the better management of the introduction 
of new high priced medicines. In Europe, for example, the 
concerning about the impact of new and emerging health 
technologies on health, health services and/or society resulted 
in the development of models to support the adoption and the 
use of new medicines for the benefit of patients32,33.
It is relevant to mention that, shortly after BOC and 
TVR incorporation, the FDA approved SOF (2013)34. 
Thus, the possibility of using new direct-acting drugs in 
a non-interferon-based regimen for a shorter period and 
with effectiveness rates above 90%9-11, may have led to a 
significant decrease in triple therapy prescriptions starting 
in 2014. The literature also describes that acquisition of 
these new medications was facilitated in Brazil, with a good 
negotiated price when compared with others countries35.
We also estimated the number of individuals that could 
have been treated, considering the quantities purchased. 
However, the available records do not allow us to 
determine how many patients were effectively treated and, 
consequently, how much of the drug remains. 
Thus, our results bring a discussion that goes beyond the 
outcomes of therapy effectiveness and safety, contributing to 
the future medical and social as well as economic analysis 
of regulatory activities and other decisions in the field of 
medication policy and treatment of hepatitis C.
The retrospective nature of the study and the reliance 
on medical records from routine clinical practice 
represent limitations of the study. Data on genetic profile, 
comorbidities and demographic characteristics such as 
skin color could not be fully recovered. Moreover, the 
multicenter character of the study also contributed to these 
losses, once each center has a different way to manage its 
services, which reflects the amount of information found 
in medical records. However, the main quality of the 
present study is the reasonable representation of real-life 
experience with triple therapy in Brazil and the importance 
of discussing the strength of scientific evidence that based 
the construction of the Brazilian guidelines for the HCV 
infection treatment. 
CONCLUSIONS
The present study demonstrates the complexity of the 
decision-making process in the context of the incorporation 
of new health technologies, especially those of high cost. 
The therapeutic and social benefits, the system sustainability 
and the return of the industry investment in the development 
of technologies are elements of a difficult solution equation. 
The decision to incorporate BOC and TVR was not 
unanimous, and due to the high cost of treatment, the clinical 
protocol limited treatment to patients in the more advanced 
stages of the disease. In clinical practice, this strategy did 
not bring significant therapeutic or social advantages over 
previous treatment and increased costs for the health system. 
Thus, this scenario suggests the necessity of the skillful 
use of implementation strategies of new pharmaceutical 
technologies to enhance the adoption and sustainability 
of a clinical program or practice that really benefits the 
population and the health care system.
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